...
首页> 外文期刊>Journal of Intensive Care >Synergistic cytoprotection by co-treatment with dexamethasone and rapamycin against proinflammatory cytokine-induced alveolar epithelial cell injury
【24h】

Synergistic cytoprotection by co-treatment with dexamethasone and rapamycin against proinflammatory cytokine-induced alveolar epithelial cell injury

机译:地塞米松和雷帕霉素共同处理对促炎性细胞因子诱导的肺泡上皮细胞损伤的协同细胞保护作用

获取原文
           

摘要

Background One of the main pathophysiological manifestations during the acute phase of sepsis is massive production of proinflammatory mediators. Clinical trials involving direct suppression of inflammatory mediators to relieve organ dysfunction in sepsis have been extensively performed; however, the clinical outcomes of such trials remain far from satisfactory. Given the need for better sepsis treatments, we have screened various agents with anti-inflammatory properties for cytoprotective effects. In this study, we identified dexamethasone and rapamycin as clinically applicable candidates with favorable synergistic effects against inflammatory cytokine-induced cytotoxicity in vitro and further explored the molecular mechanisms underlying the augmented cytoprotective effects exerted by co-treatment with both drugs. Methods Human alveolar epithelial cell-derived A549 cells were stimulated with a mixture of inflammatory cytokines, TNF-alpha, IL-1beta, and IFN-gamma, which induce cellular injury, including apoptosis. This in vitro model was designed to simulate acute lung injury (ALI) associated with sepsis. The cells were co-treated with dexamethasone and rapamycin under cytokine stimulation. Conditioned medium and cell lysates were subjected to further analysis. Results Either dexamethasone or rapamycin significantly attenuated cytokine-induced cytotoxicity in A549 cells in a dose-dependent manner. In addition, the simultaneous administration of dexamethasone and rapamycin had a synergistic cytoprotective effect. The applied doses of dexamethasone (10?nM) and rapamycin (1?nM) were considerably below the reported plasma concentrations of each drug in clinical setting. Interestingly, distinct augmentation of both of c-Jun inhibition and Akt activation were observed when the cells were co-treated with both drugs under cytokine stimulation. Conclusions A synergistic protective effect of dexamethasone and rapamycin was observed against cytokine-induced cytotoxicity in A549 cells. Augmentation of both of c-Jun inhibition and Akt activation were likely responsible for the cytoprotective effect. The combined administration of anti-inflammatory drugs such as dexamethasone and rapamycin offers a promising treatment option for alveolar epithelial injury associated with sepsis.
机译:背景技术脓毒症急性期的主要病理生理表现之一是大量产生促炎性介质。已经进行了涉及直接抑制炎症介质以减轻败血症中器官功能障碍的临床试验;然而,此类试验的临床结果仍远未令人满意。鉴于需要更好的脓毒症治疗,我们已经筛选出具有抗炎特性的多种药物来保护细胞。在这项研究中,我们确定了地塞米松和雷帕霉素是在体外具有抗炎性细胞因子诱导的细胞毒性的良好协同作用的临床应用候选药物,并进一步探讨了两种药物共同治疗所产生的增强的细胞保护作用的分子机制。方法用炎性细胞因子,TNF-α,IL-1β和IFN-γ的混合物刺激人肺泡上皮细胞衍生的A549细胞,诱导细胞损伤,包括凋亡。该体外模型旨在模拟与败血症相关的急性肺损伤(ALI)。在细胞因子刺激下,用地塞米松和雷帕霉素共同处理细胞。条件培养基和细胞裂解物进行进一步分析。结果地塞米松或雷帕霉素均以剂量依赖性方式显着减弱了A549细胞中细胞因子诱导的细胞毒性。另外,地塞米松和雷帕霉素的同时给药具有协同的细胞保护作用。地塞米松(10?nM)和雷帕霉素(1?nM)的施用剂量大大低于临床环境中每种药物的血浆浓度。有趣的是,当在细胞因子刺激下用两种药物共同处理细胞时,观察到了c-Jun抑制和Akt激活的明显增强。结论地塞米松和雷帕霉素对细胞因子诱导的A549细胞毒性具有协同保护作用。 c-Jun抑制和Akt激活的增强可能是细胞保护作用的原因。地塞米松和雷帕霉素等抗炎药的联合给药为脓毒症相关的肺泡上皮损伤提供了有希望的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号